Nanchang Hongyi Technology

Nanchang Hongyi Technology is a China-based pharmaceutical research and development company that specializes in high-end drug delivery systems and innovative small molecule therapeutics. Founded in 2002, the company has established a strong reputation for its expertise in sustained-release and controlled-release technologies, which it applies to both novel drug candidates and complex generics. Its R&D portfolio covers a wide range of therapeutic areas, including oncology, cardiovascular health, and autoimmune diseases. Notably, the company was among the first in China to develop and gain approval for complex generic versions of advanced formulations like tofacitinib citrate sustained-release tablets. Hongyi Technology operates comprehensive facilities for drug synthesis, formulation research, and quality control, positioning itself as a key player in the Chinese biotech ecosystem. The company continues to focus on bridging the gap between laboratory innovation and large-scale industrial production.